Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 323

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 323
---
 of common stock beneficially owned by our current executive officers and                                                                                                                                     
 directors and (ii) 1,368,481 shares of common stock issuable up on conversion of shares of our redeemable convertible preferred stock, (iii) warrants to purchase up to 246 shares of common stock, and (iv) 75,167 shares of common stock 
 issuable upon common stock issuable upon the exercise of options held by our current executive officers and directors within 60 days of June 30, 2025.                                                                                     |

216

DESCRIPTION OF CAPITAL STOCK

The following description of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and
restated bylaws, as each will become effective immediately prior to the closing of this offering, are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws, which are
filed as exhibits to the registration statement of which this prospectus is part.

General

Upon the closing of this offering, our authorized capital stock will consist of 500,000,000 shares of common stock, par value $0.0001 per
share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the completion of this offering will be undesignated.

As of June 30, 2025, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred
stock into an aggregate of 3,181,815 shares of our common stock upon the closing of this offering (including 382,467 additional shares of common stock issuable upon conversion of our Series C convertible preferred stock due to anti-dilution
adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus), there would have been 3,433,470 shares of common stock
issued and outstanding, held of record by 368 stockholders.

Common Stock

Voting

Each holder of common stock
is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a
majority of the voting shares are able to elect all of the directors.

Dividends

Subject to preferences that may be applicable to